Tekmira Pharmaceuticals said last week that the US Department of Defense has extended the temporary stop-work order it recently imposed on its partnership with the company to develop an RNAi-based treatment for Ebola virus infection.
Tekmira said that it now expects to hear by Sept. 30 whether the order has been lifted or extended again, or whether the government is terminating the arrangement altogether.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
